Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Plos Computational Biology
|
April 27, 2010
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
Bambang S Adiwijaya, Eva Herrmann, Brian Hare, et al.
The Journal of Infectious Diseases
|
July 22, 2008
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
Doug J Bartels, Yi Zhou, Eileen Z Zhang, et al.
British Journal of Cancer
|
October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Pamela Munster, Ian E Krop, Patricia LoRusso, et al.
Clinical Pharmacology and Therapeutics
|
April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
B S Adiwijaya, J Kim, I Lang, et al.
Annals of Internal Medicine
|
May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial
Mark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Plos One
|
April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
NPJ Systems Biology and Applications
|
July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
The Oncologist
|
April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Plos Computational Biology
|
April 27, 2010
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants
Bambang S Adiwijaya, Eva Herrmann, Brian Hare, et al.
The Journal of Infectious Diseases
|
July 22, 2008
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects
Doug J Bartels, Yi Zhou, Eileen Z Zhang, et al.
British Journal of Cancer
|
October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
Pamela Munster, Ian E Krop, Patricia LoRusso, et al.
Clinical Pharmacology and Therapeutics
|
April 27, 2017
Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer
B S Adiwijaya, J Kim, I Lang, et al.
Annals of Internal Medicine
|
May 21, 2013
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial
Mark S Sulkowski, Kenneth E Sherman, Douglas T Dieterich, et al.
Plos One
|
April 19, 2012
Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials
Tara L Kieffer, Sandra De Meyer, Doug J Bartels, et al.
NPJ Systems Biology and Applications
|
July 21, 2017
Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)
Birgit Schoeberl, Art Kudla, Kristina Masson, et al.
The Oncologist
|
April 13, 2019
Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Lecia V Sequist, Jhanelle Elaine Gray, Wael A Harb, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer
Joyce F Liu, Isabelle Ray-Coquard, Frederic Selle, et al.
Page
of 2